1. Home
  2. LBRDA vs TGTX Comparison

LBRDA vs TGTX Comparison

Compare LBRDA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation

LBRDA

Liberty Broadband Corporation

HOLD

Current Price

$33.85

Market Cap

7.2B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$53.01

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDA
TGTX
Founded
2014
1993
Country
United States
United States
Employees
1900
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
8.5B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
LBRDA
TGTX
Price
$33.85
$53.01
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$49.80
AVG Volume (30 Days)
209.5K
1.9M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
$109.28
$26.69
P/E Ratio
$8.39
$457.29
Revenue Growth
N/A
N/A
52 Week Low
$26.14
$25.37
52 Week High
$65.40
$59.30

Technical Indicators

Market Signals
Indicator
LBRDA
TGTX
Relative Strength Index (RSI) 58.64 51.91
Support Level $31.91 $51.15
Resistance Level $34.90 $58.34
Average True Range (ATR) 1.49 2.23
MACD 0.37 -0.57
Stochastic Oscillator 100.00 36.41

Price Performance

Historical Comparison
LBRDA
TGTX

About LBRDA Liberty Broadband Corporation

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: